Sanofi: gets fast track status from FDA

(CercleFinance.com) - Innate Pharma announces that Sanofi has been granted Fast Track status by the US FDA for SAR'579/IPH6101 for the treatment of hematological diseases.


Fast Track status is designed to facilitate the development and accelerate the regulatory review of drugs for the treatment of serious diseases and unmet medical needs.

SAR'579/IPH6101, the most advanced drug candidate from the ANKET platform, is a trifunctional anti-CD123 NK Cell Engager that engages the NKp46 and CD16 receptors, the result of a research collaboration between Innate Pharma and Sanofi, which is being developed by Sanofi.


Copyright (c) 2023 CercleFinance.com. All rights reserved.